339 related articles for article (PubMed ID: 26162965)
1. New immunotherapies targeting the PD-1 pathway.
Chinai JM; Janakiram M; Chen F; Chen W; Kaplan M; Zang X
Trends Pharmacol Sci; 2015 Sep; 36(9):587-95. PubMed ID: 26162965
[TBL] [Abstract][Full Text] [Related]
2. Editorial: Immunotherapies against infectious diseases.
Tufail S; Sherwani MA; Islam N
Front Med (Lausanne); 2024; 11():1426765. PubMed ID: 38818390
[No Abstract] [Full Text] [Related]
3. Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies.
Borch TH; Donia M; Andersen MH; Svane IM
Drug Discov Today; 2015 Sep; 20(9):1127-34. PubMed ID: 26189934
[TBL] [Abstract][Full Text] [Related]
4. Antagonists of PD-1 and PD-L1 in Cancer Treatment.
Lipson EJ; Forde PM; Hammers HJ; Emens LA; Taube JM; Topalian SL
Semin Oncol; 2015 Aug; 42(4):587-600. PubMed ID: 26320063
[TBL] [Abstract][Full Text] [Related]
5. Human Cancer Immunotherapy with PD-1/PD-L1 Blockade.
Zheng P; Zhou Z
Biomark Cancer; 2015; 7(Suppl 2):15-8. PubMed ID: 26448693
[TBL] [Abstract][Full Text] [Related]
6. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients.
Sui X; Ma J; Han W; Wang X; Fang Y; Li D; Pan H; Zhang L
Oncotarget; 2015 Aug; 6(23):19393-404. PubMed ID: 26305724
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory Receptors Beyond T Cell Exhaustion.
Fuertes Marraco SA; Neubert NJ; Verdeil G; Speiser DE
Front Immunol; 2015; 6():310. PubMed ID: 26167163
[TBL] [Abstract][Full Text] [Related]
8. Assays for predicting and monitoring responses to lung cancer immunotherapy.
Teixidó C; Karachaliou N; González-Cao M; Morales-Espinosa D; Rosell R
Cancer Biol Med; 2015 Jun; 12(2):87-95. PubMed ID: 26175924
[TBL] [Abstract][Full Text] [Related]
9. Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators.
Le Mercier I; Lines JL; Noelle RJ
Front Immunol; 2015; 6():418. PubMed ID: 26347741
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.
Chen L; Han X
J Clin Invest; 2015 Sep; 125(9):3384-91. PubMed ID: 26325035
[TBL] [Abstract][Full Text] [Related]
11. Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints.
Karachaliou N; Cao MG; Teixidó C; Viteri S; Morales-Espinosa D; Santarpia M; Rosell R
Cancer Biol Med; 2015 Jun; 12(2):79-86. PubMed ID: 26175923
[TBL] [Abstract][Full Text] [Related]
12. Tim-3 and Tim-4 as the potential targets for antitumor therapy.
Cheng L; Ruan Z
Hum Vaccin Immunother; 2015; 11(10):2458-62. PubMed ID: 26211834
[TBL] [Abstract][Full Text] [Related]
13. Update on checkpoint blockade therapy for lymphoma.
Kline J; Bishop MR
J Immunother Cancer; 2015; 3():33. PubMed ID: 26199729
[TBL] [Abstract][Full Text] [Related]
14. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.
Bardhan K; Anagnostou T; Boussiotis VA
Front Immunol; 2016; 7():550. PubMed ID: 28018338
[TBL] [Abstract][Full Text] [Related]
15. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.
Zou W; Wolchok JD; Chen L
Sci Transl Med; 2016 Mar; 8(328):328rv4. PubMed ID: 26936508
[TBL] [Abstract][Full Text] [Related]
17. Emerging immune checkpoints for cancer therapy.
Li X; Hu W; Zheng X; Zhang C; Du P; Zheng Z; Yang Y; Wu J; Ji M; Jiang J; Wu C
Acta Oncol; 2015 Nov; 54(10):1706-13. PubMed ID: 26361073
[TBL] [Abstract][Full Text] [Related]
18. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.
He J; Hu Y; Hu M; Li B
Sci Rep; 2015 Aug; 5():13110. PubMed ID: 26279307
[TBL] [Abstract][Full Text] [Related]
19. HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families.
Janakiram M; Chinai JM; Zhao A; Sparano JA; Zang X
Oncoimmunology; 2015 Aug; 4(8):e1026534. PubMed ID: 26405587
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.
Azoury SC; Straughan DM; Shukla V
Curr Cancer Drug Targets; 2015; 15(6):452-62. PubMed ID: 26282545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
